The expectation that synthetic biology will play a large role in shaping the future of life sciences has increased due to early successes in synthetic DNA and antibody based applications, in addition to significant focus and investment by the research community.
Synthetic biology’s impact on the healthcare industry is examined in a report, "Synthetic Biology, A New Paradigm for Biological Discovery" from Beachhead, LLC, which reveals the market for synthetic biology products and technologies as potentially one of the fastest growing segments of the life sciences market.
Although the research market is currently $600M, the potential for growth in the next 10 years is projected to expand this market to over $3.5B.
The report is based on in-depth interviews of leading scientific researchers and biotechnology executives and presents the current research and how it may be directly applied to the development of tools and systems for clinical, pharmacological and environmental applications.
It also shows that new drug applications discovered through synthetic biology have streamlined the pharmaceutical industry’s ability to deliver new therapeutic agents.
"We have been watching some of the synthetic biology markets, such as synthetic antibodies, for some time," said Richard Fisler, Director at Beachhead.
"It appeared that this industry is poised for rapid growth, and we wanted to present a holistic view of synthetic approaches, the dynamics of this market and the real applications."